Previous 10 | Next 10 |
The new year has a collection of challenges in store for the biotech sector and its investors, as pressure mounts from Washington on drug pricing practices. Along with talking points surrounding the upcoming presidential election in the US, several drug approvals and research developments wi...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) rose slightly last week from 3,759.2 points on Monday’s (December 2) open to 3,763.81 points as of 11:30 a.m. EST on Friday (December 6). On Tuesday (December 3), Cara Therapeutics (NASDAQ: CARA ) released results from a Phase 2 cli...
Gainers: Protagonist Therapeutics (NASDAQ: PTGX ) +63% . More news on: Protagonist Therapeutics, Inc., Arbutus Biopharma Corporation, Kodiak Sciences Inc., Stocks on the move, Read more ...
Bausch Health Companies (NYSE: BHC ) initiated with Neutral rating and C$40 (7% upside) price target at Goldman Sachs. Shares up 2% premarket. More news on: Bausch Health Companies Inc., Centogene N.V., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ....
Galmed Pharmaceuticals Ltd (GLMD) Q3 2019 Earnings Conference Call November 06, 2019, 08:30 ET Company Participants Allen Baharaff - Chairman, CEO & President Yohai Stenzler - CFO & Controller Liat Hayardeny - Chief Scientific Officer Tali Gorfine - Chief Medical Office...
Galmed (NASDAQ: GLMD ): Q3 GAAP EPS of -$0.21 beats by $0.09 . More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
TEL AVIV, Israel , Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral SCD1 modulator currently in a Phase 3/4 clinical trial for the ...
TEL AVIV, Israel , Oct. 31, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial fo...
TEL AVIV, Israel , Oct. 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial for the...
Quick Take 89bio ( ETNB ) has filed to raise gross proceeds of $70 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on developing and commercializing treatments for liver and cardio-metabolic diseases. ETNB plans to start Phase 2 trials in 2020 a...
News, Short Squeeze, Breakout and More Instantly...
Galmed Pharmaceuticals Ltd. Company Name:
GLMD Stock Symbol:
NASDAQ Market:
Galmed Pharmaceuticals Ltd. Website: